BiotechTube

Lutikizumab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hidradenitis Suppurativa

Conditions

Hidradenitis Suppurativa, Atopic Dermatitis

Trial Timeline

Aug 14, 2024 → Feb 1, 2027

NCT ID
NCT06524635

About Lutikizumab

Lutikizumab is a phase 2 stage product being developed by AbbVie for Hidradenitis Suppurativa. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06524635. Target conditions include Hidradenitis Suppurativa, Atopic Dermatitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06524635Phase 2Recruiting

Competing Products

20 competing products in Hidradenitis Suppurativa

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab (M1095) + AdalimumabMoonLake ImmunotherapeuticsPhase 2
47
Eltrekibart + PlaceboEli LillyPhase 2
52
Placebo + LY3041658Eli LillyPhase 2
52
Placebo + AdalimumabAbbVieApproved
85
Lutikizumab + PlaceboAbbViePhase 3
77
AdalimumabAbbViePre-clinical
23
Upadacitinib + PlaceboAbbViePhase 3
77
adalimumab + placeboAbbViePhase 3
77
adalimumabAbbViePhase 3
77
Lutikizumab + PlaceboAbbViePhase 2
52
Risankizumab + Placebo for risankizumabAbbViePhase 2
52
adalimumabAbbViePhase 3
77
adalimumab + placeboAbbViePhase 3
77
Upadacitinib + PlaceboAbbViePhase 2
52
MEDI8968 + SalineAstraZenecaPhase 2
52
AnifrolumabAstraZenecaPhase 2
52

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85